Michaeli Janna, Mandel Shira, Maximov Shelly, Zazoun Jonathan, Savoia Paola, Kothari Nimmi, Valmont Thomas, Ferrari Livia, Duncan Leonard R, Hawser Stephen, Cohen-Kutner Moshe, Bachnoff Niv
Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9270401, Israel.
Evotec Anti-Infective, Department of Microbiology Discovery, Aptuit (Verona) Srl, an Evotec Company, Via A. Fleming 4, 37135 Verona, Italy.
Antibiotics (Basel). 2022 Sep 5;11(9):1201. doi: 10.3390/antibiotics11091201.
The rapid worldwide spread of antimicrobial resistance highlights the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. This study describes the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant clinical isolates. OMN6 prevented the growth of all tested isolates, regardless of any pre-existing resistance mechanisms. Moreover, in vitro serial-passaging studies demonstrated that no resistance developed against OMN6. Importantly, OMN6 was highly efficacious in treating animal models of lung and blood infections caused by multidrug-resistant . Taken together, these results point to OMN6 as a novel antimicrobial agent with the potential to treat life-threatening infections caused by multidrug-resistant avoiding resistance.
抗菌耐药性在全球范围内迅速传播，凸显了开发创新疗法以对抗多重耐药细菌的迫切需求。本研究描述了新型肽OMN6对多种耐药临床分离株具有强大的抗菌活性。OMN6可抑制所有测试分离株的生长，无论其预先存在何种耐药机制。此外，体外连续传代研究表明，未产生对OMN6的耐药性。重要的是，OMN6在治疗由多重耐药菌引起的肺部和血液感染动物模型方面具有高效性。综上所述，这些结果表明OMN6是一种新型抗菌剂，有潜力治疗由多重耐药菌引起的危及生命的感染，且能避免耐药性产生。
